View Cancer Clinical Trials
Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
- The primary objective of this study is to determine if prophylactic administration of Lacosamide reduces the risk of seizures in patients with HGG. This will be tested in newly-diagnosed post-operative patients during the first year after tumor diagnosis. The primary endpoint will be time to first seizure.
- The secondary objectives of this study are to determine the one-year risk of first seizure in this patient population and to evaluate patient reported symptoms.
- To investigate clinical and electroencephalographic predictors of seizures in this patient population.
- To evaluate the occurrence of symptoms and correlate to seizure activity as well as tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) self-reporting tool.
- Patients with histologically confirmed supratentorial high-grade glioma will be eligible for this protocol.
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
- Patients must have signed an authorization for the release of their protected health information.
- Patients must be > 18 years old.
- Patients must have a Karnofsky performance status of ≥ 60.
- Women of childbearing potential must have a negative B-HCG pregnancy test documented within 2 weeks prior to registration.
- In the opinion of the treating investigator, patients must have adequate cognitive abilities to complete the neurocognitive components of the study.
- Patients must be able to safely swallow pills.
- Patients must agree to practice adequate contraception.
- Patients must be registered on study within 16 weeks after the surgical procedure that established the diagnosis of High Grade Glioma.
- Patients must not have any significant medical or psychiatric illnesses that in the investigator�s opinion cannot be adequately controlled with appropriate therapy or would compromise the patients ability to tolerate this therapy.
- Patients must not have serious intercurrent medical illness. Serious, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months.
- Transmural myocardial infarction within the last 6 months.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.
- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- Active connective tissue disorders, such as lupus or scleroderma, which in the opinion of the treating physician, may put the patient at high risk for radiation toxicity.
- Patients must not be pregnant or breast feeding Patients must not be pregnant because lacosamide produced developmental toxicity in rats following administration during pregnancy. There is insufficient information to determine if lacosamide is safe during lactation.
- Patients must not have any disease that will obscure toxicity or dangerously alter, Drug metabolism
- Patients must not have a history of heart block or cardiac arrhythmia, including asymptomatic arrhythmias and atrial fibrillation/flutter.
- Patients must not have a prolonged PR interval (defined as > 200 ms).
- Patients must not have used any CYP2C19 inducers or inhibitors other than perioperative prophylactic anticonvulsants for at least 2 weeks prior to registration (see section 6.1.3.d for a list). Perioperative anticonvulsants should be tapered as indicated in section 220.127.116.11.
- Patients must not have a history of any type of seizure for at least 10 years prior to registration.
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.